Hetrombopag

• CAT Number: I043733
• CAS Number: 2114365-78-3
• Molecular Formula: C25H22N4O5
• Molecular Weight: 458.47
• Purity: ≥95%
• Synonyms: 5-[2-hydroxy-3-[[3-methyl-5-oxo-1-(5,6,7,8-tetrahydronaphthalen-2-yl)-4H-pyrazol-4-yl]diazenyl]phenyl]furan-2-carboxylic acid
• IUPAC Name: 5-[2-hydroxy-3-[[5-methyl-3-oxo-2-(5,6,7,8-tetrahydronaphthalen-2-yl)-1H-pyrazol-4-yl]diazenyl]phenyl]furan-2-carboxylic acid
• InChI: InChI=1S/C25H22N4O5/c1-14-22(24(31)29(28-14)17-10-9-15-5-2-3-6-16(15)13-17)27-26-19-8-4-7-18(23(19)30)20-11-12-21(34-20)25(32)33/h4,7-13,22,30H,2-3,5-6H2,1H3,(H,32,33)
• InChIKey: YATJUTCKRWETAB-UHFFFAOYSA-N
• SMILES: CC1=C(C(=O)N(N1)C2=CC3=C(CCCC3)C=C2)N=NC4=CC=CC(=C4O)C5=CC=C(O5)C(=O)O

Hetrombopag（Cat No.:I043733）is an oral thrombopoietin receptor agonist used in the treatment of thrombocytopenia (low platelet count) associated with various conditions, including chronic immune thrombocytopenia (ITP). By binding to the thrombopoietin receptor, hetrombopag stimulates platelet production in the bone marrow, increasing platelet counts and reducing the risk of bleeding. It is particularly useful in patients who do not respond adequately to corticosteroids or other treatments. Ongoing studies aim to assess its long-term safety, efficacy, and potential use in other platelet-related disorders, making it a valuable therapeutic option for managing thrombocytopenia.